China’s CGT financing market is starting to look structured
21 companies, RMB 2.5B+ in Q1 2026 financing, and a sign that CGT capital in China is getting more selective.
China’s CGT market is entering a phase where capital is no longer just flowing. It is beginning to organize.
Key readouts
21 Chinese CGT companies completed new financings in Q1 2026
RMB 2.5B+ total disclosed financing
nearly 70% of disclosed deals were RMB 100M+ rounds
capital spread across CAR-T, TCR-T, iPSC, NK, regenerative medicine, and adjacent gene-delivery approaches
rounds included angel, Pre-A, B, C, and Pre-IPO financings
the largest disclosed round was Oricell’s approximately RMB 491M C1 financing
Why this matters
This is not just a hot financing quarter.
It is a signal that China’s CGT market is becoming broader, later-stage, and more selective.
The important shift is not more capital alone. It looks like capital is no longer just buying the story. It is starting to choose who can actually execute.
What did Q1 2026 actually show?
The biggest signal from Q1 2026 is not simply that China’s CGT market remained active. It is that the market is starting to look more structured, with financing spreading across modalities, stages, and company types.1
In Q1 2026, 21 Chinese CGT companies completed financings totaling more than RMB 2.5 billion, with nearly 70% of disclosed deals at or above the RMB 100 million level.2 Just as important, the quarter was not limited to early-stage activity. It included a mix of early-stage, mid-stage, and later-stage rounds,3 suggesting that investors were willing to finance programs beyond the earliest conceptual stage, even though financing data alone do not establish scientific validation or commercial readiness.
More broadly, this activity sits on top of a very large registration base: one industry dataset based on Qichacha reported 25,965 active or existing enterprises with “cell and gene therapy” in their business scope as of April 30, 2025.4 Surely, this should not be read as 25,965 therapeutic developers, but it does show how widely CGT-related business activity has entered China’s company-registration landscape.
Which companies pulled in the largest rounds?
Q1 2026 showed the size and seriousness of China’s CGT financing machine.
Oricell’s approximately RMB 491 million C1 round was among the largest disclosed financings of the quarter.5
Shize Biotech completed RMB 400 million in B/B+ and C1 financing for iPSC-derived allogeneic neural cell therapy.6
Regend Therapeutics raised RMB 350 million in Series C to advance regenerative medicine.7
Xinjing Zhiyuan completed an over-RMB 200 million Series B financing in solid-tumor TCR-T.8
Yimufeng completed an approximately RMB 200 million Pre-IPO financing in next-generation CAR-T.9
Other named rounds across NK, regenerative medicine, and adjacent platform categories also contributed to the quarter’s breadth.10
The point is not that one company won. The point is that capital spread across multiple modality bets while a meaningful share of larger rounds clustered in companies already advancing beyond the earliest financing stages.11
Why does modality breadth matter?
That breadth is one of the clearest signals from the quarter. The financing map spans CAR-T, TCR-T, iPSC, NK, regenerative medicine, and adjacent gene-delivery or nucleic-acid approaches.
The disease map is broad as well. It stretches from hematologic malignancies into solid tumors, CNS indications, organ regeneration, diabetes-related applications, veterinary stem-cell development, and anti-aging.12 This is what an ecosystem looks like when it starts to widen both by modality and by use case.
The quarter’s stage distribution matters even more. This was not just a seed-stage enthusiasm cycle built on concept decks and platform slogans. The quarter included angel and Pre-A financings in frontier areas, but it also included B, C, and Pre-IPO rounds.
That pattern suggests that the Chinese CGT market can support early discovery, translational build-out, and later-stage clinical execution, even though financing data alone do not establish scientific validation or commercial readiness.13
A serious ecosystem does not only fund one modality. It funds multiple competing routes to the same strategic bottleneck: scalable, controllable, accessible advanced therapies.
Is capital becoming more selective?
Just as important, the capital does not look indiscriminate.
Hot money funds categories. Selective capital funds execution.
A plausible read from Q1 is that investors are becoming more selective about what deserves real money. The companies attracting larger rounds are not just telling an exciting science story. They appear to be offering at least one of three attributes that investors may find more credible: clearer translational plans, a more manufacturable or scalable platform logic, or a more advanced path toward clinical execution. That is why Q1 2026 should not be read simply as a strong quarter for CGT financing. The better reading is that investors are starting to reward clearer translational plans, more manufacturable platform logic, and more advanced clinical execution.
You can see that in the modalities being rewarded. In CAR-T, the cited financings point to interest in groups trying to push beyond the old ex vivo, hematologic-only template and tackle harder problems around solid tumors, in vivo approaches, tumor heterogeneity, exhaustion, and the suppressive microenvironment. In iPSC, the investment case presented in the cited materials centers on off-the-shelf logic, standardization, and the possibility of industrialized production. In NK, the financing narrative is likewise tied to manufacturability, logistics, and allogeneic usability.
Across modalities, the practical question appears to be shifting from “does the biology work” to “can this biology be produced, controlled, scaled, and delivered?”14
That is the real significance of Q1 2026. The quarter suggests that China’s CGT market is moving from thematic enthusiasm toward more structured capital allocation. It is increasingly a story not only about scientific ambition, but also about platform design, manufacturing logic, regulatory progression, and financing depth lining up in the companies attracting capital.
What should global CGT readers take away?
For global CGT readers, the message is simple: China should no longer be read only as a venue for development efficiency or fast-follow platform building.
It is increasingly becoming a source of platform companies, industrial-scale ambitions, and capital-backed advanced-therapy execution.
That does not mean every one of these companies will win. It does not mean commercialization bottlenecks have disappeared. And it does not mean the category is de-risked. But it does mean that the market has become large and deep enough for capital to express real preference rather than generic excitement.
That is the bigger signal from Q1 2026: China’s CGT market is no longer just active. It is starting to look structured.
Quarter-level financing count, aggregate amount, share of RMB 100 million-plus rounds, modality spread, and stage distribution from PHIRDA/Chuangyaobang, “2026Q1 CGT Financing: 21 Companies Raised More Than RMB 2.5 Billion,” April 3, 2026, https://www.phirda.com/artilce_42141.html.
PHIRDA/Chuangyaobang, “2026Q1 CGT Financing: 21 Companies Raised More Than RMB 2.5 Billion,” April 3, 2026, https://www.phirda.com/artilce_42141.html.
PHIRDA/Chuangyaobang, “2026Q1 CGT Financing: 21 Companies Raised More Than RMB 2.5 Billion,” April 3, 2026, https://www.phirda.com/artilce_42141.html.
Zhongtou Industry Research Institute, as cited in OCN, “Cell and Gene Therapy (CGT) Is Heating Up: The Global Market Has Surpassed RMB 10 Billion, and China Is Growing Faster Than the Global Market,” August 12, 2025, https://www.ocn.com.cn/industry/latest/202508/pkvbq1293325.shtml. The article reports that, as of April 30, 2025, China had 25,965 active or existing cell-and-gene-therapy-related enterprises based on Qichacha data.
Oricell official announcement of the Series C1 financing, January 12, 2026, https://www.oricell.com/en/newsdetail/id/43.html. Converted to approximately RMB 490.8 million using the January 12, 2026 renminbi central parity rate of 7.0108 published by the People’s Bank of China and reported by China Economic Net, January 12, 2026, https://www.ce.cn/xwzx/gnsz/gdxw/202601/t20260112_2695694.shtml.
Chinaventure, “Shize Biotech completed RMB 400 million in B/B+ and C1 financing,” January 14, 2026, https://m.chinaventure.com.cn/news/111-20260114-389765.html.
36Kr, “Regend Therapeutics raised RMB 350 million in Series C,” February 11, 2026, https://www.36kr.com/p/3677602224841353
Pedaily, “Xinjing Zhiyuan completed an over-RMB 200 million Series B financing,” January 26, 2026, https://news.pedaily.cn/202601/560374.shtml.
Sina Finance, “Yimufeng completed an approximately RMB 200 million Pre-IPO financing,” March 4, 2026, https://finance.sina.com.cn/tech/roll/2026-03-04/doc-inhpusku4049902.shtml.
For the wider set of named CGT rounds in the quarter, see PHIRDA/Chuangyaobang, “2026Q1 CGT Financing: 21 Companies Raised More Than RMB 2.5 Billion,” April 3, 2026, https://www.phirda.com/artilce_42141.html.
PHIRDA/Chuangyaobang, “2026Q1 CGT Financing: 21 Companies Raised More Than RMB 2.5 Billion,” April 3, 2026, https://www.phirda.com/artilce_42141.html
For the cross-modality and cross-indication breadth in Q1 2026, see PHIRDA/Chuangyaobang, April 3, 2026, https://www.phirda.com/artilce_42141.html.
For the mix of angel, Pre-A, B, C, and Pre-IPO financings in Q1 2026, see PHIRDA/Chuangyaobang, April 3, 2026, https://www.phirda.com/artilce_42141.html
For modality-specific financing narratives in Q1 2026, see PHIRDA/Chuangyaobang, April 3, 2026, https://www.phirda.com/artilce_42141.html; see also Oricell, January 12, 2026, https://www.oricell.com/en/newsdetail/id/43.html; and Sina Finance, March 4, 2026, https://finance.sina.com.cn/tech/roll/2026-03-04/doc-inhpusku4049902.shtml.